Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
HORIZON-PFT: Pivotal Fracture Trial
- Conditions
- First Posted Date
- 2002-11-15
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 7700
- Registration Number
- NCT00049829
- Locations
- 🇺🇸
Palm Beach Research Center, West Palm Beach, Florida, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
- Conditions
- First Posted Date
- 2002-09-25
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2127
- Registration Number
- NCT00046254
- Locations
- 🇩🇪
Novartis, Nuernberg, Germany
🇺🇸Radiant Research Lake Worth, Lake Worth, Florida, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
- Conditions
- First Posted Date
- 2002-01-10
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 500
- Registration Number
- NCT00029224
- Locations
- 🇺🇸
Osceola Cancer Center, Kissimmee, Florida, United States
🇺🇸Stockton Hematology Oncology Medical Group, Stockton, California, United States
🇺🇸Hematology-Oncology Associates PC, Albuquerque, New Mexico, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.